Observational studySleep & breathing = Schlaf & Atmung2026
Ticagrelor is associated with periodic breathing during exercise in coronary patients undergoing cardiac rehabilitation: a retrospective observational study.
Observational study in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTicagrelor, a reversible P2Y12 inhibitor widely prescribed after acute coronary syndrome (ACS), induces dyspnoea and central sleep apnoea through effects on respiratory centre activity. During cardiac rehabilitation, we observed apparent ventilatory disturbances in patients receiving ticagrelor during cardiopulmonary exercise tests (CPET). This study aimed to evaluate whether ticagrelor significantly increases the risk of periodic breathing during exercise and whether this impairs functional or metabolic performance.
methodsWe performed a single-centre retrospective observational study (October 2012-December 2021) including 84 coronary patients (36 ticagrelor, 48 thienopyridines) who underwent cardiac rehabilitation following angioplasty with coronary stenting. The primary endpoint was exercise-induced periodic breathing, defined as ≥ 3 consecutive oscillation cycles of VE, VO2, or VCO2 with amplitude ≥ 30% of mean values. Secondary endpoints were peak VO2, end-tidal CO2 pressure (PETCO2), and ventilatory equivalent for CO2 (EqCO2) at peak VO2. Univariable and multivariable logistic and linear regression analyses were performed (R v4.0.0).
resultsTicagrelor was independently associated with a > 7-fold increased risk of periodic breathing during exercise in both univariable (OR = 7.82, 95% CI [2.80-24.72], p < 0.001) and multivariable analyses (OR = 7.17, 95% CI [2.31-25.19], p < 0.001), after adjustment for age, BMI, LVEF, smoking, obstructive lung disease, and neurological risk. No significant effect on PETCO2 (p = 0.759) or EqCO2 (p = 0.442) at peak VO2 was observed. In multivariable analysis, patients on ticagrelor had significantly higher peak VO2 than those on thienopyridines (+ 3.17 ml/min/kg, 95% CI [1.34-4.99], p < 0.001).
conclusionTicagrelor is significantly associated with periodic breathing during exercise in coronary patients undergoing cardiac rehabilitation. However, this ventilatory disturbance does not impair gas exchange or aerobic capacity. These findings support maintaining ticagrelor therapy in patients presenting with exercise-induced periodic breathing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.